Drugs / Ligilactobacillus salivarius MP101
Ligilactobacillus salivarius MP101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04922918 | Oct 2020 → Jun 2021 | COVID-19 | Universidad Complutense de Madrid | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ligilactobacillus salivarius MP101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04922918 ↗ |
| Modality | Other / unclassified | “Probiotic arm” NCT04922918 ↗ |
| Route | Oral | “Administration of the strain through a fermented milk” NCT04922918 ↗ |